l General Information |
Product Name | GSK2636771 |
General description | GSK2636771 is a potent, orally bioavailable and selective inhibitor of PI3Kβ. |
Synonym | 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid; GSK-2636771 |
Purity | ≥98%(HPLC) | CAS Number | 1372540-25-4 |
Formula | C22H22F3N3O3 | Molecular Weight | 433.431 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Pale yellow solid |
Solubility(25℃) | DMSO | ≥20mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | GSK2636771 is a potent, orally bioavailable and selective inhibitor of PI3Kβ with >900-fold selectivity over PI3Kα/PI3Kγ and >10-fold over PI3Kδ. Sensitive to PTEN null cell lines. |
Application | GSK2636771 has been used in trials studying the treatment of CANCER, LYMPHOMA, Solid Neoplasm, Recurrent Solid Neoplasm, and Advanced Malignant Neoplasm, among others. |
l Packaging & Storage |
Packaging | 5mg; 25mg |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
